K
43.52
0.33 (0.76%)
| Previous Close | 43.19 |
| Open | 43.00 |
| Volume | 496,380 |
| Avg. Volume (3M) | 448,000 |
| Market Cap | 3,298,631,424 |
| Price / Earnings (TTM) | 96.71 |
| Price / Earnings (Forward) | 31.95 |
| Price / Sales | 5.52 |
| Price / Book | 6.07 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Kiniksa Pharmaceuticals, Ltd. | Bearish | Bullish |
AIStockmoo Score
0.2
| Analyst Consensus | 1.0 |
| Insider Activity | -4.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.20 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (TD Cowen, 37.87%) | Buy |
| Median | 50.00 (14.89%) | |
| Low | 44.00 (Wedbush, 1.10%) | Buy |
| Average | 50.80 (16.73%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 37.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 29 Oct 2025 | 55.00 (26.38%) | Buy | 37.38 |
| Citigroup | 17 Oct 2025 | 50.00 (14.89%) | Buy | 38.64 |
| Wedbush | 13 Oct 2025 | 44.00 (1.10%) | Buy | 37.03 |
| TD Cowen | 29 Sep 2025 | 60.00 (37.87%) | Buy | 38.77 |
| Wells Fargo | 25 Sep 2025 | 45.00 (3.40%) | Buy | 35.51 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| QUART BARRY D | - | 41.55 | -20,129 | -836,360 |
| TESSARI EBEN | - | 41.55 | -12,048 | -500,594 |
| Aggregate Net Quantity | -32,177 | |||
| Aggregate Net Value ($) | -1,336,954 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 41.55 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TESSARI EBEN | Officer | 15 Dec 2025 | Automatic sell (-) | 12,048 | 41.55 | 500,594 |
| TESSARI EBEN | Officer | 15 Dec 2025 | Option execute | 6,000 | - | - |
| QUART BARRY D | Director | 15 Dec 2025 | Automatic sell (-) | 20,129 | 41.55 | 836,360 |
| QUART BARRY D | Director | 15 Dec 2025 | Option execute | 20,129 | - | - |
| Date | Type | Details |
|---|---|---|
| 12 Nov 2025 | Announcement | Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London |
| 28 Oct 2025 | Announcement | Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution |
| 23 Oct 2025 | Announcement | Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 |
| 17 Oct 2025 | Announcement | Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |